| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2014-02-548610 |
| P8608 | Fatcat ID | release_6xjkkqory5cmdjl76oegpga22y |
| P932 | PMC publication ID | 4046423 |
| P698 | PubMed publication ID | 24659631 |
| P5875 | ResearchGate publication ID | 261035046 |
| P50 | author | Stefania Pittaluga | Q87358458 |
| P2093 | author name string | Adrian Wiestner | |
| Stella Chang | |||
| Mohammed Farooqui | |||
| Rashida Z Mustafa | |||
| Sarah E M Herman | |||
| Betty Chang | |||
| Jennifer A Gyamfi | |||
| P2860 | cites work | The role of toll-like receptors in chronic B-cell malignancies | Q37578343 |
| The role of Tec family kinases in mononuclear phagocytes | Q37578585 | ||
| Signalling crosstalk in B cells: managing worth and need | Q37586125 | ||
| Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). | Q37596620 | ||
| Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy | Q37655012 | ||
| Nurture versus nature: the microenvironment in chronic lymphocytic leukemia | Q37967256 | ||
| Bruton tyrosine kinase (BTK) and its role in B-cell malignancy | Q37997075 | ||
| BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity | Q39056302 | ||
| A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies | Q40020213 | ||
| Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. | Q40465454 | ||
| A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. | Q42094298 | ||
| BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway | Q42748357 | ||
| B-cell receptor signaling in chronic lymphocytic leukemia. | Q50674847 | ||
| Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. | Q51025698 | ||
| Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. | Q54478992 | ||
| Ibrutinib in relapsed chronic lymphocytic leukemia | Q86036824 | ||
| Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia | Q24599100 | ||
| Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma | Q24613755 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| Chronic lymphocytic leukemia | Q28236621 | ||
| Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling | Q28272891 | ||
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 | ||
| Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia | Q33394487 | ||
| Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial | Q33412064 | ||
| In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells | Q33830733 | ||
| Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 | ||
| Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase | Q34001339 | ||
| Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy | Q34020276 | ||
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 | ||
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 | ||
| Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. | Q34289493 | ||
| Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation | Q34542087 | ||
| The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia | Q34542102 | ||
| Syk mediates BCR- and CD40-signaling integration during B cell activation | Q34786499 | ||
| Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma | Q35146262 | ||
| Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen | Q35849244 | ||
| Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia | Q36462375 | ||
| Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. | Q36562876 | ||
| Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications | Q36862781 | ||
| Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. | Q37003535 | ||
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes | Q37226729 | ||
| Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation | Q37328562 | ||
| Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. | Q37576591 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | NF-κB | Q411114 |
| ibrutinib | Q5984881 | ||
| P1104 | number of pages | 10 | |
| P304 | page(s) | 3286-3295 | |
| P577 | publication date | 2014-03-21 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL | |
| P478 | volume | 123 |
| Q35794593 | A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia |
| Q55061968 | A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. |
| Q91735722 | A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia |
| Q93023511 | An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL |
| Q36548443 | Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function |
| Q39383524 | Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management |
| Q34041311 | BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future |
| Q38729031 | BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia |
| Q46217363 | Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats. |
| Q90256133 | Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma |
| Q30383411 | CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. |
| Q50121608 | Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. |
| Q42700845 | Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling |
| Q93039099 | Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL |
| Q38708220 | Chronic lymphocytic leukemia: Time to go past genomics? |
| Q33774517 | Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib |
| Q55001348 | Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. |
| Q40397638 | Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia |
| Q89776891 | Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL |
| Q46074725 | Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. |
| Q91259857 | Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL |
| Q39100263 | Construction of a lncRNA-PCG bipartite network and identification of cancer-related lncRNAs: a case study in prostate cancer |
| Q39129372 | Current Treatment of Chronic Lymphocytic Leukemia. |
| Q52684522 | Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase II study. |
| Q90871224 | Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment |
| Q36759124 | Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study |
| Q37706530 | Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment |
| Q39028378 | Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. |
| Q48307279 | Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia |
| Q38394750 | Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia. |
| Q36782516 | Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib |
| Q37066202 | Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Reply |
| Q64120393 | Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL |
| Q49818504 | Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment |
| Q42091318 | Ibrutinib and rituximab induced rapid response in refractory Richter syndrome |
| Q36490049 | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia |
| Q38998430 | Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia |
| Q46689848 | Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia |
| Q38694168 | Ibrutinib for mantle cell lymphoma |
| Q33419580 | Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial |
| Q49714593 | Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia |
| Q39414732 | Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. |
| Q33909648 | Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma |
| Q38585329 | Ibrutinib-A double-edge sword in cancer and autoimmune disorders. |
| Q92314359 | Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia |
| Q39010883 | Ibrutinib: A Review in Chronic Lymphocytic Leukaemia |
| Q38388594 | Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia |
| Q64068098 | Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson |
| Q54979047 | Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. |
| Q42368314 | Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach |
| Q36337598 | Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib |
| Q36520447 | Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments. |
| Q36437030 | Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. |
| Q57287569 | Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma |
| Q47674917 | MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia |
| Q49912101 | Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia |
| Q35781530 | Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia |
| Q36918248 | Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment |
| Q51822007 | NF-κB p50 (nfkb1) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia. |
| Q90292254 | Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL |
| Q39290199 | Novel agents in mantle cell lymphoma |
| Q43185847 | Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients. |
| Q91608178 | Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis |
| Q90424234 | PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR |
| Q36253983 | Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib |
| Q38544216 | Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly |
| Q39200835 | Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax |
| Q53963822 | Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q36867755 | Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade |
| Q38345576 | Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma |
| Q60955103 | Rac GTPases in Hematological Malignancies |
| Q92630079 | Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk |
| Q97524840 | Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents |
| Q47163960 | SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia |
| Q38765458 | Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. |
| Q94671635 | Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies |
| Q36091288 | Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib |
| Q36245171 | T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice. |
| Q93376490 | TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib |
| Q27002528 | Targeted therapies in CLL: mechanisms of resistance and strategies for management |
| Q92158076 | Targeting B-cell receptor signaling in leukemia and lymphoma: how and why? |
| Q97593212 | Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody |
| Q47988466 | Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy |
| Q38809539 | Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. |
| Q38862584 | Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells |
| Q27025812 | Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib |
| Q92163322 | The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment |
| Q46566477 | The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia |
| Q90284007 | The CXCR4-CXCL12-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro |
| Q35489417 | The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia |
| Q26775506 | The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia |
| Q38728157 | The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma |
| Q36172601 | Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo |
Search more.